NO325824B1 - Efavirenz-kapsler eller -tabletter som omfatter et desintegreringsmiddel og en fremgangsmate for fremstilling av disse. - Google Patents
Efavirenz-kapsler eller -tabletter som omfatter et desintegreringsmiddel og en fremgangsmate for fremstilling av disse. Download PDFInfo
- Publication number
- NO325824B1 NO325824B1 NO20005043A NO20005043A NO325824B1 NO 325824 B1 NO325824 B1 NO 325824B1 NO 20005043 A NO20005043 A NO 20005043A NO 20005043 A NO20005043 A NO 20005043A NO 325824 B1 NO325824 B1 NO 325824B1
- Authority
- NO
- Norway
- Prior art keywords
- efavirenz
- capsule
- present
- weight
- amount
- Prior art date
Links
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 title claims description 52
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 title claims description 51
- 229960003804 efavirenz Drugs 0.000 title claims description 51
- 239000002775 capsule Substances 0.000 title claims description 44
- 239000007884 disintegrant Substances 0.000 title claims description 34
- 238000000034 method Methods 0.000 title claims description 20
- 230000008569 process Effects 0.000 title claims description 4
- 238000002360 preparation method Methods 0.000 title description 2
- 238000005550 wet granulation Methods 0.000 claims description 40
- 239000003826 tablet Substances 0.000 claims description 29
- 239000008109 sodium starch glycolate Substances 0.000 claims description 28
- 229920003109 sodium starch glycolate Polymers 0.000 claims description 28
- 229940079832 sodium starch glycolate Drugs 0.000 claims description 28
- 238000004519 manufacturing process Methods 0.000 claims description 22
- 239000007891 compressed tablet Substances 0.000 claims description 19
- 239000002552 dosage form Substances 0.000 claims description 17
- 239000000314 lubricant Substances 0.000 claims description 13
- 229920000881 Modified starch Polymers 0.000 claims description 12
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 12
- 235000019426 modified starch Nutrition 0.000 claims description 12
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 12
- 238000007580 dry-mixing Methods 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 239000003085 diluting agent Substances 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 7
- 239000004368 Modified starch Substances 0.000 claims description 6
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 6
- 229960000913 crospovidone Drugs 0.000 claims description 6
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 6
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 239000011230 binding agent Substances 0.000 claims description 5
- 239000011734 sodium Substances 0.000 claims description 5
- 229910052708 sodium Inorganic materials 0.000 claims description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 claims description 4
- 229940083542 sodium Drugs 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- 238000000227 grinding Methods 0.000 claims description 3
- 239000000203 mixture Substances 0.000 description 24
- 239000002245 particle Substances 0.000 description 18
- 238000009472 formulation Methods 0.000 description 17
- 239000000463 material Substances 0.000 description 14
- 239000000126 substance Substances 0.000 description 10
- 239000007963 capsule composition Substances 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 239000007909 solid dosage form Substances 0.000 description 9
- 229920002472 Starch Polymers 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000008187 granular material Substances 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 235000019698 starch Nutrition 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 7
- 238000004090 dissolution Methods 0.000 description 7
- 239000007903 gelatin capsule Substances 0.000 description 7
- 238000005469 granulation Methods 0.000 description 7
- 230000003179 granulation Effects 0.000 description 7
- 239000008186 active pharmaceutical agent Substances 0.000 description 6
- 235000010980 cellulose Nutrition 0.000 description 6
- 229920002678 cellulose Polymers 0.000 description 6
- 229940088679 drug related substance Drugs 0.000 description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 description 6
- 229940032147 starch Drugs 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 241000725303 Human immunodeficiency virus Species 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 239000001913 cellulose Substances 0.000 description 5
- 208000030507 AIDS Diseases 0.000 description 4
- -1 clays Polymers 0.000 description 4
- 238000007906 compression Methods 0.000 description 4
- 230000006835 compression Effects 0.000 description 4
- 229920006037 cross link polymer Polymers 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000006186 oral dosage form Substances 0.000 description 3
- 239000007916 tablet composition Substances 0.000 description 3
- 208000031886 HIV Infections Diseases 0.000 description 2
- 108010078851 HIV Reverse Transcriptase Proteins 0.000 description 2
- 208000037357 HIV infectious disease Diseases 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000009509 drug development Methods 0.000 description 2
- 238000009478 high shear granulation Methods 0.000 description 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000012907 medicinal substance Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000009736 wetting Methods 0.000 description 2
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000012254 powdered material Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8092598P | 1998-04-07 | 1998-04-07 | |
| PCT/US1999/007228 WO1999051239A1 (en) | 1998-04-07 | 1999-04-01 | Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20005043L NO20005043L (no) | 2000-10-06 |
| NO20005043D0 NO20005043D0 (no) | 2000-10-06 |
| NO325824B1 true NO325824B1 (no) | 2008-07-21 |
Family
ID=22160544
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20005043A NO325824B1 (no) | 1998-04-07 | 2000-10-06 | Efavirenz-kapsler eller -tabletter som omfatter et desintegreringsmiddel og en fremgangsmate for fremstilling av disse. |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US6238695B1 (xx) |
| EP (1) | EP1067936B1 (xx) |
| JP (1) | JP2002510634A (xx) |
| KR (1) | KR100634253B1 (xx) |
| CN (1) | CN1146419C (xx) |
| AR (1) | AR019031A1 (xx) |
| AT (1) | ATE223719T1 (xx) |
| AU (1) | AU756422B2 (xx) |
| BR (1) | BR9908810A (xx) |
| CA (1) | CA2321523C (xx) |
| CZ (1) | CZ300850B6 (xx) |
| DE (1) | DE69902893T2 (xx) |
| DK (1) | DK1067936T3 (xx) |
| EA (1) | EA003217B1 (xx) |
| EE (1) | EE04391B1 (xx) |
| ES (1) | ES2181417T3 (xx) |
| HU (1) | HU228498B1 (xx) |
| IL (1) | IL138078A (xx) |
| NO (1) | NO325824B1 (xx) |
| NZ (1) | NZ507566A (xx) |
| PL (1) | PL194309B1 (xx) |
| PT (1) | PT1067936E (xx) |
| SK (1) | SK284655B6 (xx) |
| TW (1) | TW576741B (xx) |
| UA (1) | UA72207C2 (xx) |
| WO (1) | WO1999051239A1 (xx) |
| ZA (1) | ZA200004313B (xx) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA72207C2 (uk) * | 1998-04-07 | 2005-02-15 | Брістол- Майєрс Сквібб Фарма Компані | Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення |
| EP1332757B1 (en) * | 1998-05-27 | 2012-06-13 | Merck Sharp & Dohme Corp. | Efavirenz compressed tablet formulation |
| US20010014352A1 (en) | 1998-05-27 | 2001-08-16 | Udit Batra | Compressed tablet formulation |
| KR20070040426A (ko) * | 1998-06-11 | 2007-04-16 | 파마시아 앤드 업존 캄파니 엘엘씨 | 빠르게 침전하는 약물의 정제 제제 |
| US20050053678A1 (en) * | 2001-10-03 | 2005-03-10 | Gow Robert T. | Methods and compositions for betel nut chewing gum |
| US20050069596A1 (en) * | 2001-10-03 | 2005-03-31 | Gow Robert T. | Compositions and methods comprising kava and anti-anxiety compounds |
| US7291352B2 (en) | 2001-10-03 | 2007-11-06 | Herbalscience Llc | Methods and compositions for oral delivery of Areca and mate' or theobromine |
| US7037524B2 (en) * | 2001-10-03 | 2006-05-02 | Herbalscience, Llc | Oral delivery of a botanical |
| EP1448170A4 (en) * | 2001-11-27 | 2010-05-12 | Bristol Myers Squibb Co | EFAVIRENZ STAMP PREPARATIONS HAVING UNIQUE BIOPHARMACEUTICAL CHARACTERISTICS |
| FR2834212B1 (fr) * | 2001-12-27 | 2004-07-09 | Besins Int Belgique | Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques |
| GB0209265D0 (en) | 2002-04-23 | 2002-06-05 | Novartis Ag | Organic compounds |
| US20050037025A1 (en) * | 2002-10-03 | 2005-02-17 | Gow Robert T. | Methods and compositions comprising kava and mate' or theobromine |
| US20040224916A1 (en) | 2003-01-14 | 2004-11-11 | Gilead Sciences, Inc. | Compositions and methods for combination antiviral therapy |
| US8021682B2 (en) * | 2004-08-13 | 2011-09-20 | Gallipot, Inc. | Palatable suspending vehicle for pharmaceutical ingredients |
| US20060099253A1 (en) * | 2004-10-20 | 2006-05-11 | Wyeth | Antibiotic product formulation |
| TWI375560B (en) * | 2005-06-13 | 2012-11-01 | Gilead Sciences Inc | Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same |
| TWI471145B (zh) | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
| EP1912730A2 (en) * | 2005-07-28 | 2008-04-23 | Isp Investments Inc. | Method to improve characteristics of spray dried powders and granulated materials, and the products thereby produced |
| WO2007013047A2 (en) * | 2005-07-29 | 2007-02-01 | Ranbaxy Laboratories Limited | Water-dispersible anti-retroviral pharmaceutical compositions |
| AU2006325404B2 (en) * | 2005-12-14 | 2012-03-01 | Cipla Limited | Pharmaceutical combination comprising nucleotide and nucleoside reverse transcriptase inhibitors (such as tenofovir and lamivudine) in different parts of the dosage unit |
| EP2043613A1 (en) * | 2006-07-14 | 2009-04-08 | Fmc Corporation | Solid form |
| MX2009002873A (es) * | 2006-09-14 | 2009-05-19 | Chemlink Lab Llc | Metodo para preparar formas de dosis solida que forman una pasta, crema o gel cuando se diluyen para uso final. |
| US20080152717A1 (en) * | 2006-12-14 | 2008-06-26 | Isp Investments, Inc. | Amorphous valsartan and the production thereof |
| US8613946B2 (en) * | 2006-12-21 | 2013-12-24 | Isp Investment Inc. | Carotenoids of enhanced bioavailability |
| US10189957B2 (en) * | 2007-01-26 | 2019-01-29 | Isp Investments Llc | Formulation process method to produce spray dried products |
| US20080181961A1 (en) * | 2007-01-26 | 2008-07-31 | Isp Investments, Inc. | Amorphous oxcarbazepine and the production thereof |
| US20080311162A1 (en) * | 2007-05-16 | 2008-12-18 | Olivia Darmuzey | Solid form |
| JP2010536798A (ja) * | 2007-08-17 | 2010-12-02 | テバ ファーマシューティカル インダストリーズ リミティド | 難溶性薬物の生体利用率を制御するための方法及び組成物 |
| WO2010008719A2 (en) * | 2008-06-16 | 2010-01-21 | Schering Corporation | Oral pharmaceutical formulations of vla-4 antagonists |
| WO2010125572A1 (en) * | 2009-04-29 | 2010-11-04 | Hetero Research Foundation | Compressed tablets and capsules containing efavirenz |
| NZ627826A (en) | 2010-01-27 | 2016-01-29 | Viiv Healthcare Co | Antiviral combinations involving (3s,11ar)-n-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide |
| NZ602955A (en) * | 2010-04-20 | 2015-02-27 | Cipla Ltd | Pharmaceutical composition comprising efavirenz |
| US20130115237A1 (en) | 2010-06-09 | 2013-05-09 | Vaccine Technologies, Incorporated | Therapeutic immunization in hiv infected subjects to augment antiretroviral treatment |
| CN102872019A (zh) * | 2012-09-17 | 2013-01-16 | 北京阜康仁生物制药科技有限公司 | 一种采用微粉化技术的依非韦伦制剂 |
| IN2013MU03370A (xx) | 2013-10-25 | 2015-09-25 | Cipla Ltd | |
| PE20180690A1 (es) | 2015-04-27 | 2018-04-23 | Intercept Pharmaceuticals Inc | Composiciones de acido obeticolico y metodos de uso |
| WO2017029226A1 (en) | 2015-08-14 | 2017-02-23 | Sandoz Ag | Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz |
| CN114404377B (zh) * | 2022-01-10 | 2023-07-25 | 安徽贝克生物制药有限公司 | 一种阿巴卡韦、拉米夫定、依非韦伦复方片及其制备方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7084587A (en) | 1986-04-01 | 1987-10-20 | Upjohn Company, The | Methylprednisolone/sodium carboxymethyl starch tablet composition |
| CA2002137A1 (en) * | 1989-04-28 | 1990-10-28 | Genkichi Ohta | Anti-human immunodeficiency virus composition |
| DK0577913T3 (da) * | 1992-07-08 | 1998-01-26 | Santen Oy | Ophthalmisk præparat indeholdende timolol-hemihydrat |
| US5519021A (en) | 1992-08-07 | 1996-05-21 | Merck & Co., Inc. | Benzoxazinones as inhibitors of HIV reverse transcriptase |
| US5455045A (en) * | 1993-05-13 | 1995-10-03 | Syntex (U.S.A.) Inc. | High dose formulations |
| AU1694295A (en) * | 1994-01-28 | 1995-08-15 | Merck & Co., Inc. | Benzoxazinones as inhibitors of hiv reverse transcriptase |
| US5663467A (en) * | 1995-01-23 | 1997-09-02 | Merck & Co., Inc. | Synthesis of cyclopropylacetylene |
| IT1281502B1 (it) * | 1995-06-13 | 1998-02-18 | Sardinian Antiviral Research C | Impiego di un inibitore non nucleosidico della trascrittasi inversa in associazione con inibitori nucleosidici per il trattamento della |
| UA72207C2 (uk) * | 1998-04-07 | 2005-02-15 | Брістол- Майєрс Сквібб Фарма Компані | Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення |
| PE20000559A1 (es) | 1998-05-27 | 2000-07-05 | Merck & Co Inc | Formulacion de tabletas comprimidas de efavirenz |
-
1999
- 1999-01-04 UA UA2000105657A patent/UA72207C2/uk unknown
- 1999-04-01 EE EEP200000589A patent/EE04391B1/xx unknown
- 1999-04-01 ES ES99916286T patent/ES2181417T3/es not_active Expired - Lifetime
- 1999-04-01 HU HU0101517A patent/HU228498B1/hu unknown
- 1999-04-01 IL IL13807899A patent/IL138078A/xx not_active IP Right Cessation
- 1999-04-01 SK SK1461-2000A patent/SK284655B6/sk not_active IP Right Cessation
- 1999-04-01 DE DE69902893T patent/DE69902893T2/de not_active Expired - Lifetime
- 1999-04-01 AU AU34637/99A patent/AU756422B2/en not_active Expired
- 1999-04-01 PL PL99343421A patent/PL194309B1/pl unknown
- 1999-04-01 KR KR1020007011091A patent/KR100634253B1/ko not_active IP Right Cessation
- 1999-04-01 DK DK99916286T patent/DK1067936T3/da active
- 1999-04-01 NZ NZ507566A patent/NZ507566A/xx not_active IP Right Cessation
- 1999-04-01 PT PT99916286T patent/PT1067936E/pt unknown
- 1999-04-01 CA CA002321523A patent/CA2321523C/en not_active Expired - Lifetime
- 1999-04-01 JP JP2000542010A patent/JP2002510634A/ja active Pending
- 1999-04-01 EP EP99916286A patent/EP1067936B1/en not_active Expired - Lifetime
- 1999-04-01 AT AT99916286T patent/ATE223719T1/de active
- 1999-04-01 CN CNB998048011A patent/CN1146419C/zh not_active Ceased
- 1999-04-01 EA EA200001030A patent/EA003217B1/ru not_active IP Right Cessation
- 1999-04-01 BR BR9908810-0A patent/BR9908810A/pt not_active Application Discontinuation
- 1999-04-01 WO PCT/US1999/007228 patent/WO1999051239A1/en active IP Right Grant
- 1999-04-01 CZ CZ20003571A patent/CZ300850B6/cs not_active IP Right Cessation
- 1999-04-06 US US09/286,902 patent/US6238695B1/en not_active Expired - Lifetime
- 1999-04-07 AR ARP990101586A patent/AR019031A1/es not_active Application Discontinuation
- 1999-06-09 TW TW088105520A patent/TW576741B/zh not_active IP Right Cessation
-
2000
- 2000-08-22 ZA ZA200004313A patent/ZA200004313B/xx unknown
- 2000-10-06 NO NO20005043A patent/NO325824B1/no not_active IP Right Cessation
-
2001
- 2001-04-02 US US09/824,071 patent/US6555133B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO325824B1 (no) | Efavirenz-kapsler eller -tabletter som omfatter et desintegreringsmiddel og en fremgangsmate for fremstilling av disse. | |
| EP1275391B1 (en) | Pharmaceutical compositions containing irbesartan and a diuretic | |
| JP2720932B2 (ja) | 経口投与用アセトアミノフエン錠剤の製造法及びアセトアミノフエン二層錠剤 | |
| NO331689B1 (no) | Oral farmasoytisk sammensetning omfattende rivastigmin, samt anvendelse av rivastigmin | |
| AU2005324132A1 (en) | Solid, orally applicable pharmaceutical administration forms containing rivaroxaban having modified release | |
| MX2012004903A (es) | Composiciones farmaceuticas solidas que contienen un hinibidor de la integrasa. | |
| NO175884B (no) | Fremgangsmåte for fremstilling av en presset tablett som inneholder methylprednisolon og et super-desintegrasjonsmiddel | |
| JP2011168596A (ja) | トラネキサム酸製剤 | |
| US4863741A (en) | Tablet composition for drug combinations | |
| EA008585B1 (ru) | Капсулы флуконазола с улучшенным высвобождением | |
| RU2694056C2 (ru) | Противотуберкулезная стабильная фармацевтическая композиция в форме диспергируемой таблетки, содержащей гранулированный изониазид и гранулированный рифапентин, и способ ее приготовления | |
| NO331480B1 (no) | Farmasoytiske sammensetninger med kontrollert frigivelse | |
| TW201315462A (zh) | 異丁苯丙酸可嚼錠 | |
| EP0196002B1 (en) | Tablet composition for drug combinations | |
| CN105407875A (zh) | 包含异烟肼颗粒和利福喷汀颗粒的呈包衣片剂形式的抗结核病的稳定的药物组合物及其制备方法 | |
| MXPA00009817A (en) | Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants | |
| AU2021275675A1 (en) | Pharmaceutical composition | |
| EP3153157A1 (en) | Pharmaceutical composition for prolonged release of nevirapine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |